This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Arthritis Therapeutics Market To 2018 - Novel Oral JAK Inhibitors And Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications

Scope

- Data and analysis of the arthritis market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan. - Annualized market data for the osteoarthritis, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis markets from 2004 to 2010, with forecasts to 2018.- Market Data on geographical landscape and therapeutic landscape including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.- Key drivers and restraints that have had a significant impact on the market - The competitive landscape of the arthritis market which includes companies such as Johnson & Johnson, Abbott, Amgen, Pfizer, Roche and Bristol-Myers Squibb.- Key M&A activities and licensing agreements that took place from 2005 to 2011 in the arthritis market.

Reasons to buy

- Align your product portfolio to the markets with high growth potential.- Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.- Device a more tailored country strategy by understanding the key drivers and barriers of the arthritis market.- Develop key strategic initiatives by understanding the key focus areas of the leading companies.- Accelerate and strengthen your market position by identifying the key companies for mergers, acquisitions and strategic partnerships.

Table of Contents

1 Table of Contents1 Table of Contents 61.1 List of Tables 91.2 List of Figures 112 Arthritis Therapeutics Market to 2018 - Introduction 123 Arthritis Therapeutics Market to 2018 - Market Overview 143.1 Introduction 143.2 Revenue Forecasts for the Global Arthritis Therapeutics Market 153.2.1 Revenue 153.2.2 Annual Cost of Treatment 163.3 Treatment Usage Patterns 173.3.1 Diseased Population 183.3.2 Treatment Seeking Population 183.3.3 Diagnosis Population 183.3.4 Prescription Population 194 Arthritis Therapeutics Market to 2018 - Therapeutic Landscape 204.1 Osteoarthritis Therapeutics Market 204.1.1 Introduction 204.1.2 Epidemiology 214.1.3 Symptoms 214.1.4 Diagnosis 214.1.5 Diagnostic Imaging Techniques 224.1.6 Treatment 224.1.7 Revenue 254.1.8 Annual Cost of Treatment 264.1.9 Treatment Usage Patterns 274.1.10 Marketed Products 294.2 Drivers and Barriers for the Osteoarthritis Therapeutics Market 304.2.1 Drivers for the Osteoarthritis Therapeutics Market 304.2.2 Barriers for the Osteoarthritis Therapeutics Market 304.3 Opportunity and Unmet Need 314.4 Arthritis Therapeutics Market 324.4.1 Introduction 324.4.2 Epidemiology 334.4.3 Symptoms 334.4.4 Diagnosis 344.4.5 Diagnostic Techniques 344.4.6 Treatment 354.4.7 Non-Pharmacological Therapy 364.4.8 Surgical Treatment 364.4.9 Pharmacological Therapy 364.4.10 Revenue 374.4.11 Annual Cost of Treatment 384.4.12 Treatment Usage Patterns 394.4.13 Marketed products 414.5 Drivers and Barriers for the Rheumatoid Arthritis Therapeutics Market 424.5.1 Drivers for the Rheumatoid Arthritis Therapeutics Market 424.5.2 Barriers for the Rheumatoid Arthritis Therapeutics Market 424.6 Opportunity and Unmet Needs 434.7 Psoriatic Arthritis Therapeutics Market 434.7.1 Introduction 434.7.2 Epidemiology 444.7.3 Symptoms 444.7.4 Diagnosis 444.7.5 Diagnostic Techniques 444.7.6 Treatment 454.7.7 Non-Pharmacological Therapy 454.7.8 Pharmacological Therapy 454.7.9 Surgery 464.7.10 Revenue 464.7.11 Annual Cost of Treatment 474.7.12 Treatment Usage Patterns 484.7.13 Marketed Products 504.8 Drivers and Barriers for the Psoriatic Arthritis Therapeutics Market 514.8.1 Drivers for the Psoriatic Arthritis Therapeutics Market 514.8.2 Barriers for the Psoriatic Arthritis Therapeutics Market 514.9 Opportunity and Unmet Needs 514.10 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Market 524.10.1 Introduction 524.10.2 Epidemiology 524.10.3 Symptoms 534.10.4 Diagnosis 534.10.5 Treatment 544.10.6 Non-Pharmacological Therapy 544.10.7 Pharmacological Therapy 554.10.8 Surgery 564.10.9 Revenue 564.10.10 Annual Cost of Treatment 574.10.11 Treatment Usage Patterns 584.10.12 Marketed products 604.11 Drivers and Barriers for the Ankylosing Spondylitis Therapeutics Market 604.11.1 Drivers for the Ankylosing Spondylitis Therapeutics Market 604.11.2 Barriers for the Ankylosing Spondylitis Therapeutics Market 604.12 Opportunity and Unmet Need 615 Arthritis Therapeutics Market to 2018 - Geographical Landscape 625.1 Revenue Analysis by Geography 625.2 The US 635.2.1 Revenue 635.2.2 Annual Cost of Treatment 655.2.3 Treatment Usage Patterns 665.3 Top Five European countries (UK, Germany, France, Italy and Spain) 685.3.1 Revenue 685.3.2 Annual Cost of Treatment 695.3.3 Treatment Usage Patterns 705.4 Japan 725.4.1 Revenue 725.4.2 Annual Cost of Treatment 735.4.3 Treatment Usage Patterns 746 Arthritis Therapeutics Market to 2018 - Product Pipeline Analysis 766.1 Introduction 786.1.1 Research and Development Pipeline – Osteoarthritis 786.2 Introduction 836.2.1 Research and Development Pipeline – Rheumatoid Arthritis 836.3 Introduction 956.3.1 Research and Development Pipeline – Psoriasis Arthritis 956.4 Introduction 966.4.1 Research and Development Pipeline – Ankylosing Spondylitis 966.5 Profiles of Promising Drugs in the Pipeline 986.5.1 Tofacitinib (CP-690550) 986.5.2 Ofatumumab 996.5.3 Secukinumab (AIN457) 996.5.4 Fostamatinib (R788) 1006.5.5 LY2127399 (Tabalumab) 1016.5.6 REGN88 (SAR153191) 1026.5.7 LT-NS001 1037 Arthritis Therapeutics Market to 2018 - Competitive Landscape 1047.1 Market Share Analysis 1047.1.1 Major Players 1047.2 Competitive Profile 1057.2.1 Roche 1057.2.2 Johnson & Johnson 1077.2.3 Pfizer 1087.2.4 Abbott Laboratories 1107.2.5 Bristol-Myers Squibb 1117.2.6 Amgen 1128 Arthritis Therapeutics Market to 2018 - Strategic Consolidations 1138.1 Mergers and Acquisitions 1138.1.1 Overview 1138.1.2 Major Merger and Acquisition Deals 1138.1.3 Possible Future Merger and Acquisition Deals 1198.2 Licensing Agreements 1208.2.1 Overview 1208.2.2 Major Licensing Deal 1208.3 Co-Development Agreements 1268.4 Deals by Geography 1328.5 Deals by Value 1339 Arthritis Therapeutics Market to 2018 - Appendix 1349.1 Market Definitions 1349.2 Abbreviations 1349.3 Sources 1359.4 Research Methodology 1369.4.1 Coverage 1369.4.2 Secondary Research 1369.4.3 Primary Research 1379.4.4 Forecasts 1379.4.5 Expert Panel Validation 1409.5 Contact Us 1409.6 Disclaimer 140

List of Tables

Table 1: Arthritis Therapeutics Market, Global, Revenue ($bn), 2004-2010 15

Table 2: Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2018 16

2 of 7

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs